Cargando…
The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting
An extended‐release opioid analgesic (OxyContin, OC) was reformulated with abuse‐deterrent properties to deter abuse. This report examines changes in abuse through oral and nonoral routes, doctor‐shopping, and fatalities in 10 studies 3.5 years after reformulation. Changes in OC abuse from 1 year be...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102571/ https://www.ncbi.nlm.nih.gov/pubmed/27170195 http://dx.doi.org/10.1002/cpt.390 |
_version_ | 1782466446108917760 |
---|---|
author | Coplan, PM Chilcoat, HD Butler, SF Sellers, EM Kadakia, A Harikrishnan, V Haddox, JD Dart, RC |
author_facet | Coplan, PM Chilcoat, HD Butler, SF Sellers, EM Kadakia, A Harikrishnan, V Haddox, JD Dart, RC |
author_sort | Coplan, PM |
collection | PubMed |
description | An extended‐release opioid analgesic (OxyContin, OC) was reformulated with abuse‐deterrent properties to deter abuse. This report examines changes in abuse through oral and nonoral routes, doctor‐shopping, and fatalities in 10 studies 3.5 years after reformulation. Changes in OC abuse from 1 year before to 3 years after OC reformulation were calculated, adjusted for prescription changes. Abuse of OC decreased 48% in national poison center surveillance systems, decreased 32% in a national drug treatment system, and decreased 27% among individuals prescribed OC in claims databases. Doctor‐shopping for OC decreased 50%. Overdose fatalities reported to the manufacturer decreased 65%. Abuse of other opioids without abuse‐deterrent properties decreased 2 years later than OC and with less magnitude, suggesting OC decreases were not due to broader opioid interventions. Consistent with the formulation, decreases were larger for nonoral than oral abuse. Abuse‐deterrent opioids may mitigate abuse and overdose risks among chronic pain patients. |
format | Online Article Text |
id | pubmed-5102571 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-51025712016-11-14 The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting Coplan, PM Chilcoat, HD Butler, SF Sellers, EM Kadakia, A Harikrishnan, V Haddox, JD Dart, RC Clin Pharmacol Ther Research An extended‐release opioid analgesic (OxyContin, OC) was reformulated with abuse‐deterrent properties to deter abuse. This report examines changes in abuse through oral and nonoral routes, doctor‐shopping, and fatalities in 10 studies 3.5 years after reformulation. Changes in OC abuse from 1 year before to 3 years after OC reformulation were calculated, adjusted for prescription changes. Abuse of OC decreased 48% in national poison center surveillance systems, decreased 32% in a national drug treatment system, and decreased 27% among individuals prescribed OC in claims databases. Doctor‐shopping for OC decreased 50%. Overdose fatalities reported to the manufacturer decreased 65%. Abuse of other opioids without abuse‐deterrent properties decreased 2 years later than OC and with less magnitude, suggesting OC decreases were not due to broader opioid interventions. Consistent with the formulation, decreases were larger for nonoral than oral abuse. Abuse‐deterrent opioids may mitigate abuse and overdose risks among chronic pain patients. John Wiley and Sons Inc. 2016-06-22 2016-09 /pmc/articles/PMC5102571/ /pubmed/27170195 http://dx.doi.org/10.1002/cpt.390 Text en © 2016 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of The American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Coplan, PM Chilcoat, HD Butler, SF Sellers, EM Kadakia, A Harikrishnan, V Haddox, JD Dart, RC The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting |
title | The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting |
title_full | The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting |
title_fullStr | The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting |
title_full_unstemmed | The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting |
title_short | The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting |
title_sort | effect of an abuse‐deterrent opioid formulation (oxycontin) on opioid abuse‐related outcomes in the postmarketing setting |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102571/ https://www.ncbi.nlm.nih.gov/pubmed/27170195 http://dx.doi.org/10.1002/cpt.390 |
work_keys_str_mv | AT coplanpm theeffectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting AT chilcoathd theeffectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting AT butlersf theeffectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting AT sellersem theeffectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting AT kadakiaa theeffectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting AT harikrishnanv theeffectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting AT haddoxjd theeffectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting AT dartrc theeffectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting AT coplanpm effectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting AT chilcoathd effectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting AT butlersf effectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting AT sellersem effectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting AT kadakiaa effectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting AT harikrishnanv effectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting AT haddoxjd effectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting AT dartrc effectofanabusedeterrentopioidformulationoxycontinonopioidabuserelatedoutcomesinthepostmarketingsetting |